At a glance
- Originator Maxia Pharmaceuticals
- Developer Maxia Pharmaceuticals; Nonindustrial source
- Class Antineoplastics
- Mechanism of Action Apoptosis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Breast cancer
Most Recent Events
- 24 Jun 2001 No-Development-Reported for Breast cancer in USA (Unknown route)
- 07 Oct 1998 Preclinical development for Breast cancer in USA (Unknown route)